Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. - Wikidata - wikimedia - TriplyDB

Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.

Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.

http://www.wikidata.org/entity/Q33267448

about

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy Systemic therapies for pancreatic cancer--the role of pharmacogenetics Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use Irinotecan pharmacogenomics Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology.Urinary elimination of coproporphyrins is dependent on ABCC2 polymorphisms and represents a potential biomarker of MRP2 activity in humans UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.Pharmacogenetics and pharmacogenomics of anticancer agents.Effect of ABCC2 (MRP2) transport function on erythromycin metabolism Contribution of tumoral and host solute carriers to clinical drug response.Efflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis.Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo Pharmacogenetic pathway analysis of docetaxel elimination.Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysis Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples.Impact of pharmacogenomics on clinical practice in oncology.Molecular markers of chemotherapeutic response and toxicity in colorectal cancer.Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2).Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.A perspective on efflux transport proteins in the liver Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?PhRMA white paper on ADME pharmacogenomics.Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.The role of transporters in the pharmacokinetics of orally administered drugs.The effects of ABCC2 G1249A polymorphism on the risk of resistance to antiepileptic drugs: a meta-analysis of the literature.Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice.Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?Pharmacogenetics of drug transporters in the enterohepatic circulation.Personalized medicine policy challenges: measuring clinical utility at point of care.Exploring the Carbamazepine Interaction with Human Pregnane X Receptor and Effect on ABCC2 Using in Vitro and in Silico Approach.

P2860

Q24651239-8165F1F7-3D86-46EE-8525-794E83E1C12D Q26775949-7AF46DDE-E195-480E-812C-FE882F1BC633 Q26851060-93176721-1BD6-4398-96BD-589B5ED85218 Q27021716-B0AB3606-CDE2-45B4-887B-38D8960BD3AF Q28068930-0D9BD8D0-25F3-4707-9BC1-66B4BF2000B7 Q28287024-47215F9C-87D7-4E94-998C-31BA0228D727 Q28535089-0977A33A-E57D-49C1-8BF2-51E5C9647153 Q28542007-E837E116-8EFC-4EFD-AA60-D000106BFB96 Q28943493-4B14DC28-AAA8-43EC-9263-63A820C8E34C Q30318822-63034FB0-EF8F-41A7-8DF5-566E689F3A4D Q34065294-64DDBC42-0551-42A9-ACA5-7AAA4084B502 Q34071782-756365E5-90E8-405B-9414-5BEA6F262D26 Q34897941-42F31869-71CC-45AC-AAAD-21AE32AEF797 Q34984788-61016D9E-049F-4016-ADB8-0AC568F0B08D Q35008045-7979B0EE-BFD2-4398-9915-D27B7ABF75EE Q35030489-04CE2FC1-5EF1-4F04-91AD-D5412D17617F Q35902300-FB975D9E-0E92-4606-B700-D5A3860B9FFF Q35946876-9490C02D-FD7B-4791-BBA4-990DA701356C Q36043023-0A6741BD-65C6-454B-A929-E56DA633C064 Q36051757-AA5F8EBF-5908-4D20-97FC-550135336D53 Q36182023-51BC3357-8B37-4072-B78D-DFEDBB243D00 Q36281662-EC6B5EB3-25D0-49F6-9D59-99A3879DB24F Q36352809-83B46962-00FC-482D-BA0C-250CDE30F9BB Q36684423-4C0C6037-A223-4643-94F4-A25DA1B93502 Q36775605-8AA2CCEC-B9D1-4EA7-8048-0B64257E2C32 Q36788481-4B4E5BBB-08D9-4672-A415-15EE3CFFC382 Q36806579-BA7512D8-D018-4C3E-A923-66A0A6FCC696 Q36885663-72EF469D-B60B-43A7-8ED2-9E47CB6BCDC3 Q36943992-8B76CFFC-0CEA-4BC1-9EA3-45C248D5DEC6 Q37050337-C2213DB0-3A33-4120-BD8D-B36361E0238E Q37173199-677688FA-72F4-42AF-A698-F83C2D868118 Q37182212-5CDBDED3-425C-416C-A04B-EE02395264A4 Q37481450-BED75A62-8357-4E59-B3E0-57CCE94FAA2A Q37537018-2B3B05A9-EAFF-4B9C-802F-12D2C0B283EA Q37587940-F98314E6-01C6-4921-8108-C75FC222A390 Q37734911-0854F953-8427-4D87-9F64-8057715566BF Q37834445-ECE0FA38-83A1-40C5-B65B-D1A711B302D6 Q37880875-2CBEDF85-E6D4-45D0-A4A4-B3AA504EE425 Q38027568-1CE036C5-1048-45A6-8E69-856DEAE1FC06 Q38706504-EEE9DB37-3694-465B-8F9E-FB58859EE902

P2860

Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.

http://www.wikidata.org/entity/Q33267448

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Irinotecan-induced diarrhea: f ...... hic ABCC2 transporter protein.

@ast

Irinotecan-induced diarrhea: f ...... hic ABCC2 transporter protein.

@en

type

label

Irinotecan-induced diarrhea: f ...... hic ABCC2 transporter protein.

@ast

Irinotecan-induced diarrhea: f ...... hic ABCC2 transporter protein.

@en

prefLabel

Irinotecan-induced diarrhea: f ...... hic ABCC2 transporter protein.

@ast

Irinotecan-induced diarrhea: f ...... hic ABCC2 transporter protein.

@en

P1433

Q33267448-D537A38E-E809-4B19-9649-967E974D3C35

P1476

Q33267448-F1856F8E-025E-4625-B870-F771F6B036EA

P2093

Q33267448-08591CF2-534D-47FB-8F3D-487C39076C4C

Q33267448-31559F6B-EF27-4276-9AC2-C1B23D1CE40C

Q33267448-91532078-23CF-445F-831C-7712DE465DA0

Q33267448-9C09FEB4-CFB5-49E5-AB15-D2AEB0F03360

Q33267448-A94FEBB5-A9D1-42AF-8B29-0D8CCCB0EDD2

Q33267448-C0ADFC1C-734A-43A8-BCBA-1D63400B933D

Q33267448-CDD5D94A-9D3B-4749-8822-C27E9D4E7DE4

Q33267448-DEC0233E-F011-4859-A67F-F20212FE1655

Q33267448-FBD8F5ED-32CE-4AB9-854A-00E981B94353

P2860

Q33267448-6F05A77F-F7A9-4B07-8AC7-4052B0D7DF85

Q33267448-890DE20B-AB51-4D66-948B-6170ACBF4D93

Q33267448-991E5C9D-FB7B-4168-BB9F-9DAE0376A12F

Q33267448-DA4B2186-DFB1-43D7-A7A7-0F64E5CDCCE2

Q33267448-FD280EBA-B6A3-488F-9250-4DEF6EC35A13

P304

Q33267448-30320F07-0ADD-42BD-993D-4FA1F319F246

P31

Q33267448-641A375C-03D2-4964-AC1B-894228C88388

P356

Q33267448-9DD1D1E6-0F90-499B-8892-2B4E20883CB2

P407

Q33267448-37D760B0-23BD-417D-B277-C4E9A321EE10

P433

Q33267448-EA58A9B0-7853-4C1A-8F55-F45B81D59C94

P478

Q33267448-B1992655-C8ED-4304-AD7F-37BC68BA10D0

P577

Q33267448-B413908A-4640-43EE-ABA0-945B398FB39D

P5875

Q33267448-246EF6CE-62E1-493B-B49B-20A99D42F606

P698

Q33267448-AC571034-E0F0-4C26-9829-6FB36B0EF657

P921

Q33267448-B464D1A4-5521-45CC-9A0B-D59978B13A67

P356

SJ.CLPT.6100019

P1433

Clinical Pharmacology & Therapeutics

P1476

Irinotecan-induced diarrhea: f ...... hic ABCC2 transporter protein.

@en

P2093

A Sparreboom

http://www.w3.org/2001/XMLSchema#string

D L Kroetz

http://www.w3.org/2001/XMLSchema#string

F A de Jong

http://www.w3.org/2001/XMLSchema#string

H L McLeod

http://www.w3.org/2001/XMLSchema#string

J Verweij

http://www.w3.org/2001/XMLSchema#string

L E Friberg

http://www.w3.org/2001/XMLSchema#string

R H Mathijssen

http://www.w3.org/2001/XMLSchema#string

S Marsh

http://www.w3.org/2001/XMLSchema#string

T J Scott-Horton

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of St. John's wort on irinotecan metabolism.

Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain.

CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein

Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.

Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.

P304

42-49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.CLPT.6100019

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6614431

http://www.w3.org/2001/XMLSchema#string

P698

17185998

http://www.w3.org/2001/XMLSchema#string

P921

Afọ ọsịsa